---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-024906"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-04-13T23:59:59+00:00"
generated_at: "2026-05-15T06:35:29.622853+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Spyre reports preliminary $741M cash; suspends ATM offering

## Summary
- Preliminary cash, equivalents and marketable securities of $741M as of March 31, 2026.
- Includes $30M legacy asset disposition proceeds; $23M expected to be paid to CVR holders in Q2 2026.
- Effective April 13, 2026, terminated ATM prospectus; no further share sales under Sales Agreement until new filing.
- Sales Agreement with TD Securities remains in force; company funded without current need for dilution.

## SEC filing metadata
- accession: 0001628280-26-024906
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/syre-20260413.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-024906
- JSON: https://secwatch.observer/filing/0001628280-26-024906.json
- Plain text: https://secwatch.observer/filing/0001628280-26-024906.txt

## Source-grounded claims
- claim_id: 75b5b8d23c8dd3ad0dd09aa34b58c89dd242cddb
  claim: Spyre Therapeutics, Inc. reported preliminary financial results for the quarter ended March 31, 2026.
  evidence_excerpt: the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.